Cellectis Reports First Quarter 2025 Financial Results and Business Update
Biotechnology company Cellectis has released its financial results for the first quarter of 2025 and provided an update on its development programs. The company's cash position stood at $246 million as of March 31.
New York – May 12, 2025 – Cellectis, a clinical-stage biotechnology company, has announced its financial results for the first quarter of 2025 and provided a business update.
The company expects to present Phase 1 data and a late-stage development strategy for lasme-cel (UCART22) in the third quarter of 2025. The ongoing Phase 1 study for eti-cel (UCART20x22) in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) is anticipated to have a readout in late 2025.
Research and development activities are continuing under its partnership with AstraZeneca across three programs: an allogeneic CAR T-cell therapy for hematological malignancies, one for solid tumors, and an in vivo gene therapy for a genetic disorder.
Cellectis will also present new research on non-viral gene editing and base editing at the American Society of Gene and Cell Therapy (ASGCT) annual meeting. The company's cash position was $246 million as of March 31, 2025, providing runway into the second half of 2027.